NCT00002663 2023-02-13Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or MalignanciesAtara BiotherapeuticsPhase 1/2 Completed58 enrolled 18 charts
NCT01805037 2021-09-01Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNorthwestern UniversityPhase 1/2 Terminated20 enrolled 17 charts